Indacaterol (Arcapta Neohaler) for COPD

Medical Letter on Drugs and Therapeutics

Volumn 54, Issue 1389, 2012, Pages 33-34

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ARFORMOTEROL; BUDESONIDE PLUS FORMOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE; INDACATEROL; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE; 5 (2 (5,6 DIETHYLINDAN 2 YLAMINO) 1 HYDROXYETHYL) 8 HYDROXY 1H QUINOLIN 2 ONE; 5-(2-(5,6-DIETHYLINDAN-2-YLAMINO)-1-HYDROXYETHYL)-8-HYDROXY-1H-QUINOLIN-2-ONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; INDAN DERIVATIVE; QUINOLONE DERIVATIVE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; FORCED EXPIRATORY VOLUME; HEADACHE; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; INSOMNIA; LETTER; MAINTENANCE THERAPY; NAUSEA; OROPHARYNX PAIN; QT PROLONGATION; RHINOPHARYNGITIS; TACHYCARDIA; TREMOR; ARTICLE; INHALATIONAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; HUMANS; INDANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES;

EID: 84862588493     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (6)

1. Drugs for chronic obstructive pulmonary disease. Treat Guidel Med Lett 2010; 8:83.
2. EM Kerwin et al. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged >40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies. Clin Ther 2011; 33:1974.
3. S Korn et al. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med 2011; 105:719.
4. R Buhl et al. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J 2011; 38:797.
5. JF Donohue et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182:155.
6. BA Chowdhury et al. The risks and benefits of indacaterol - the FDA's review. N Engl J Med 2011; 365:2247.